Focus on human microbiome to fight liver cirrhosis

22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.

Learn more

First patient included in ALB-TRIAL

We are happy to report that the first patient was included in the ALB-TRIAL! The ALB-TRIAL is a trial investigating whether a biomarker can predict which patients will benefit from treatment with albumin. Patients will be admitted for participation in Hungary, Spain, Germany, Denmark, Belgium, The Netherlands and the UK. Find out more about the trial here.


Read more

More news

MICROB-PREDICT 6th General Assembly Meeting in Ljubljana, Slovenia

MICROB-PREDICT's 6th General Assembly (GA) Meeting will take place from 20 to 22 March 2024 in beautiful Ljubljana, Slovenia.
During the meeting, work package leaders will not only present and discuss the overall status of their respective work package, but we will also have an intensive paper-writing workshop as well as amazing Masterclasses.
We look forward to three productive days!

More events

MICROB-PREDICT: The project in 3 minutes

(by scientific coordinator Jonel Trebicka)